Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune ...

Boehringer Ingelheim has launched a new range of cat and dog supplements under the Seraquin brand. The three supplements ...

Brian Hilberdink, a pharmaceutical industry veteran, recently assumed the role of President, U.S. Human Pharma, at Boehringer Ingelheim. Hilberdink recently sat down for an informal Q&A on his new ...

German pharmaceutical giant Boehringer Ingelheim said China remains a market of continued interest and would keep up the ...

“We are very pleased to embark on this collaboration and license agreement with Boehringer Ingelheim,” said Daniel Passeri, Chief Executive Officer of Cue Biopharma. “This partnership with ...

The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and ...